Munger Mode rating: 2 out of 5 — Sell. Our own rating from the research report below, on business quality first: moat durability and management, with price separating the top three.
We have looked at GE HealthCare the way we look at everything: first ask whether this is a wonderful business, and only then ask about price. Our answer is that it is not a wonderful business. It is a decent, durable, entirely average one — a respectable oligopolist in medical imaging with one genuinely attractive segment (Pharmaceutical Diagnostics), one large mediocre segment (imaging equipment), and one segment currently losing money (Patient Care Solutions). It carries roughly $8 billion of net debt plus about $5 billion of legacy postretirement obligations inherited from General Electric, converts only about 60 cents of each reported earnings dollar into free cash, and just demonstrated — via a $245 million tariff hit it could not price through — that its pricing power is thinner than its market position suggests. The stock is not expensive.
Recent filings analysed: 8-K (2026-08-18), 8-K (2026-07-29), 10-Q (2026-07-29), 8-K (2026-07-29).
Stock screener · Superinvestor 13F holdings · Analyst sentiment · Market valuation